Study of ATP-binding cassette transporter A1 (ABCA1)-mediated cellular cholesterol efflux in diabetic golden hamsters

Journal of International Medical Research

Volumn 35, Issue 4, 2007, Pages 508-516

  Zhu, Y ^a   Wang, H J ^a   Chen, L F ^a   Fang, Q ^a   Yan, X W ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Apolipoprotein A 1 (ApoA 1); Atorvastatin; ATP binding cassette transporter protein A1 (ABCA1); Cellular cholesterol efflux; Lipid lowering agents; Macrophage; Type 2 diabetes mellitus

Indexed keywords

8 BROMO CYCLIC AMP; ABC TRANSPORTER A1; APOLIPOPROTEIN A1; ATORVASTATIN; CHOLESTEROL; CHOLESTEROL ESTERASE; CHOLESTEROL OXIDASE; CYCLIC AMP; MESSENGER RNA; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG MECHANISM; HAMSTER; IN VITRO STUDY; INSULIN RESISTANCE; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STREPTOZOCIN DIABETES; UPREGULATION;

EID: 34547888342     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000703500410     Document Type: Article

References (28)

1. Gordon T, Castelli WP, Hjortland MC, et al: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-714.
2. Assmann G, Schulte H: Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992; 70: 733-737.
3. Luc G, Bard JM, Ferrières J, et al: Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/ A-II in prediction of coronary heart disease: the PRIME study. Arterioscler Thromb Vasc Biol 2002; 22: 1155-1161.
4. Gwynne JT: High-density lipoprotein cholesterol levels as a marker of reverse cholesterol transport. Am J Cardiol 1989; 64: 10G-17G.
5. Yancey PG, Bortnick AE, Kellner-Weibel G, et al: Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003; 23:712-719.
6. Lewis GF, Rader DJ: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005; 96: 1221-1232.
7. Fitzgerald ML, Okuhira K, Short III GF, et al: ATP-binding cassette transporter A1 contains a novel C-terminal VFVNFA motif that is required for its cholesterol efflux and ApoA-I binding activities. J Biol Chem 2004; 279: 48477-48485.
8. Oram JF: HDL apolipoproteins and ABCA1: partners in the removal of excess cellular cholesterol. Arterioscler Thromb Vasc Biol 2003; 23: 720-727.
9. Ando H, Tsuruoka S, Yamamoto H, et al: Effects of pravastatin on the expression of ATP-binding cassette transporter A1. J Pharmacol Exp Ther 2004; 311: 420-425.
10. Zanotti I, Favari E, Sposito AC, et al: Pitavastatin increases ABCA1-mediated lipid efflux from Fu5AH rat hepatoma cells. Biochem Biophys Res Commun 2004; 321: 670-674.
11. Wong J, Quinn CM, Brown AJ: Statins inhibit synthesis of an oxysterol ligand for the liver x receptor in human macrophages with consequences for cholesterol flux. Arterioscler Thromb Vasc Biol 2004; 24: 2365-2371.
12. Argmann CA, Edwards JY, Sawyez CG, et al: Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem 2005; 280: 22212 -22221.
13. Zanotti I, Poti F, Favari E, et al: Pitavastatin effect on ATP binding cassette A1-mediated lipid efflux from macrophages: evidence for liver X receptor (LXR)-dependent and LXR-independent mechanisms of activation by cAMP. J Pharm Exp Ther 2006; 317: 395-401.
14. Alexander CM, Landsman PB, Teutsch SM: Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. Am J Cardiol 2000; 86: 897-902.
15. Saydah SH, Eberhardt MS, Loria CM, et al: Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol 2002; 156: 714-719.
16. Windler E: What is the consequence of an abnormal lipid profile in patients with type 2 diabetes or the metabolic syndrome? Atheroscler Suppl 2005; 6: 11-14.
17. Kuchler M, Silver L: Antidyslipidemic action of fenofibrate in dyslipidemic-diabetic hamster model. Biochem Biophys Res Commun 2003; 305: 215-222.
18. Wang PR, Guo Q, Ippolito M, et al: High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists. Eur J Pharmacol 2001; 427: 285-293.
19. Contreras JA, Castro M, Bocos C, et al: Combination of an enzymatic method and HPLC for the quantitation of cholesterol in cultured cells. J Lipid Res 1992; 33: 931-936.
20. Wang N, Silver DL, Costet P, et al: Specific binding of ApoA1, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem 2000; 275: 33053-33058.
21. Ansell BJ, Navab M, Hama S, et al: Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from coronary subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108: 2751-2756.
22. Zheng L, Nukuna B, Brennan ML, et al: Apolipoprotein A-1 is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004; 114: 529-541.
23. van Leuven SI, Kastelein JJ. Atorvastatin: Expert Opin Pharmacother 2005; 6: 1191-1203.
24. Okazaki S, Yokoyama T, Miyauchi K, et al: Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during hall a year after coronary event: the ESTABLISH Study. Circulation 2004; 110: 1061-1068.
25. Bortnick AE, Rothblat GH, Stoudt G, et al: The correlation of ATP binding cassette 1 mRNA levels with cholesterol efflux from various cell lines. J Biol Chem 2000; 275: 28634-28640.
26. Llaverias G, Lacasa D, Vinals M, et al: Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin. Biochem Pharmacol 2004; 68: 155-163.
27. Kumar AP, Reynolds WF: Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun 2005; 331: 442-451.
28. Ghosh S, St Clair RW, Rudel LL: Mobilization of cytoplasmic CE droplets by overexpression of human macrophage cholesteryl ester hydrolase. J Lipid Res 2003; 44: 1833-1840.